Incyte (INCY) shared its earnings report 30 days ago. What can we expect for the stock moving forward?
Incyte has announced encouraging results from two phase III trials that tested Opzelura for treating prurigo nodularis in adults.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AAD2025--Incyte has shared the findings from their Phase 3 clinical trials that tested Ruxolitinib Cream 1.5% (Opzelura®) for patients suffering from Prurigo Nodularis (PN).
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte has announced inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4).
Incyte's earnings for the fourth quarter of 2024 were mixed, with revenue slightly exceeding expectations but non-GAAP earnings falling short. The stock price has dropped because the guidance for 2025 was lower than anticipated. However, Incyte's future looks promising with four product launches planned for 2025 and the potential for an additional $1 billion in revenue by 2029, along with a solid history of revenue growth and over 10 significant product launches expected by 2030.
Incyte has shared its fourth-quarter 2024 results, which show a mix of outcomes: earnings fell short of expectations, but revenues exceeded them. The sales growth compared to last year is mainly due to Jakafi and Opzelura.
Incyte Corporation will hold its Q4 2025 Earnings Conference Call on February 10, 2025, at 8:00 AM ET. Key company leaders, including the CEO and CFO, will participate, along with various analysts from major financial institutions. The call will provide a financial and corporate update, and participants will be in listen-only mode during the presentation.
While the revenue and earnings per share (EPS) for Incyte (INCY) provide insight into its performance for the quarter ending December 2024, it could be helpful to look at how these important figures stack up against Wall Street predictions and last year's results.
Incyte (INCY) reported quarterly earnings of $1.43 per share, which is lower than the Zacks Consensus Estimate of $1.53 per share. This is an increase compared to earnings of $1.06 per share from the same period last year.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte has announced its financial results for the fourth quarter and the entire year of 2024, along with its financial outlook for 2025 and key research and development milestones for that year.